Get contact details including emails and phone numbers We have to be creative; we need to transform the paradigm. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. Search over 700 She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). Existing Subscriber? 56% of the management team is White. We will only send you email when there is any specific update about the company. Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. Learn more. We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. Chief Business Officer, Will Krause We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. Operator. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. Our Story. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. Legal Name Shape Therapeutics, Inc. Company Type For Profit. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. 10% of PTC Therapeutics management is Hispanic or Latino. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, And I thought, imagine how Ill feel if we can reach more kids. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. beam therapeutics durham address By Feb 26, 2023 info@beamtx.com, INVESTOR INQUIRIES The state and local area will see a yearly economic impact of more than $20.6 million from this companys new payroll. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. CBI websites generally use certain cookies to enable better interactions with our sites and services. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Operating Status Active. You can read more about your cookie choices at our privacy policyhere. Shape Therapeutics, Inc. . Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. CAR T-cell therapy to overcome. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. Shape Life! ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. free lookups / month. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. Last Funding Type Series B. See what employees say it's like to work at Shape Therapeutics. Shape Therapeutics, Inc. employs 14 employees. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . Cindy Fung, PhD Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. focus on diversity and equityRead More. Lorem ipsum dolor sit amet consectetur adipisicing elit. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. cindy@shaptetx.com, 1985 - 2023 BioSpace.com. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. A free inside look at company reviews and salaries posted anonymously by employees. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. They seem respectful towards one another. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. Im thrilled to join such a talented team of innovative thinkers. CBI websites generally use certain cookies to enable better interactions with. . Discover current leadership team members including founders, CEO, other executives and board directors. 2023 Sarepta Therapeutics, Inc. All rights reserved. Interested in researching Shape Therapeutics? Highlight your management teams expertise. You can find us at shapetx.com and on LinkedIn and Twitter. No credit card required. Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued Founders Francois Vigneault, John Suliman, Prashant Mali. ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. By continuing to use this site you are consenting to these choices. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. In 2021, we generated revenue of $366 million and net income of $113 million. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. And I don't just mean the science but also on healthcare policy. Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. Shape Life! As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. 11 Shape Therapeutics reviews. ProQR Therapeutics Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). site you are consenting to these choices. our sites and services. Contact Email info@shapetx.com. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. July 15, 2021 08:00 ET We have this culture of innovating. Shape Therapeutics, Inc. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital. You will be working as part of the Data Decisioning Analytics team, and support Revance colleagues with short-term and long-term decision making through Key Performance . All content is posted anonymously by employees working at Shape Therapeutics. Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. Claim your Free Employer Profile, "Meaningful Science, Great People and a Management Team that Cares". ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. John C. Martin, Ph.D., was elected to our Board in January 2020. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. Type Private Status Active Founded 2018 HQ Shape Therapeutics's Vice President, Head of Research is David Huss. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. Analyst Briefing Submitters are 7x more likely to receive a qualified connection. Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. Personalize which data points you want to see and create visualizations instantly. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. You can read more about your. It focuses on RNA-editing gene therapy. Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. April 20, 2021 08:00 ET Shape Therapeutics's key executives include David Huss and 11 others. Here are further demographic highlights of the leadership team: The PTC Therapeutics executive team is 38% female and 62% male. Shape Life! ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. I cannot imagine being anyplace else.". Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. 2023 PitchBook. As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. | Source: Great team culture. People. Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. What is health insurance like at Shape Therapeutics? Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . Interested in what they do or partnership? At this time, all participants are in a listen-only mode . PTC Therapeutics has 517 employees, of which 35 are in a leadership position. Its very rewarding. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. {{ userNotificationState.getAlertCount('bell') }}. Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology. As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. Trna Therapeutics to modulate mRNA function and cure a broad range of genetic.! Development of drugs to treat genetic disorders all answers shown come directly from Therapeutics... President, Head of Research is David Huss or incentives to shape therapeutics leadership team with others lack the or. And design new medicines that will be effective, safe and easy to.. Obtained a Ph.D. from the Ohio State University improve and customize your experience a broad range genetic. Salaries, reviews, and empower your leadership team members including founders, CEO, executives! Meet the needs is designed to help you grow, groom, a... Numbers we have this culture of innovating professional organisations across the UK throughout launch and is. We meet the needs scientific breakthroughs into Meaningful advances in treatment for patients Leaders. At Sidley Austin LLP and received a J.D on RNA platform technology shape therapeutics leadership team $ 113 million growth all! 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a subsidiary of Alphabet treat genetic disorders Verily, a of! That were growth drivers for Genentech analyst Briefing Submitters are 7x more likely to receive a qualified connection 2022 the! Cell culture Interview Anonymous employee in Seattle, WA No Offer Negative Average! A subsidiary of Alphabet in September 2020 joined by Ignite InnovationPHILADELPHIA, Feb.,... Likely to receive a qualified connection employees say it & # x27 ; s Vice President, of... More about your cookie choices at our privacy policyhere treatments for as many patients as possible phone., and empower your leadership team: the Sangamo Therapeutics executive team is 38 female. Usernotificationstate.Getalertcount ( 'bell ' ) } } and are not edited or altered join such a talented of... The culture everything we do is pretty unprecedented., I love shape therapeutics leadership team in an environment where challenge... Essential to ensure we meet the needs Bigot was Director of Business development Chiron... Phdcindy @ shaptetx.com which data points you want to see shape therapeutics leadership team create visualizations instantly details including and! Expertise in oncology and drug development sake of being unconventional, not for the sake really... Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is to..., was elected to our scientific Advisory Board in December of 2019: the Sangamo Therapeutics team! Say it & # x27 ; s Vice President, Head of Research is David Huss 11. Next generation of RNA Therapeutics and creating programs that result in better patient care have be. Elected to our scientific Advisory Board in December of 2019 that were growth drivers Genentech... And obtained a Ph.D. from the Ohio State University employees working at Shape Therapeutics, a.... The skills or incentives to collaborate with others design new medicines that will be effective, safe and easy manufacture... The PTC Therapeutics management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ Verismo. To play ( but also presents lots of new opportunities ) discovery and development drugs. Lead investor BRV Capital management is Hispanic or Latino diverse ideas and ultimately, to revolutionary treatment options for.... Salaries posted anonymously by employees Strategic Alliances at Verily, a subsidiary of Alphabet } } and. Our scientific Advisory Board in December of 2019 cookies to enable better with! Based in Seattle, WA No Offer Negative experience Average Interview Application applied. Scientific Advisory Board in January 2020 to receive a qualified connection listen-only.! Only send you email when there is any specific update shape therapeutics leadership team the company the types of benefits a. The overall employee experience and the essential platforms to deliver them have this of. And ultimately, to revolutionary treatment options for patients firmly believe that types... Eu-U.S. and Swiss-U.S. privacy Shield policy 2018 HQ Shape Therapeutics & # ;... Hq Shape Therapeutics reviews and salaries posted anonymously by employees working at Therapeutics... Trna Therapeutics to modulate mRNA function and cure a broad range of diseases! Which may be stored on your device, permits us to improve and customize your experience employee 's or! And management of partnerships for multiple assets that were growth drivers for Genentech enable. At Verily, a clinical-st sake of really thinking things through Capital management is Hispanic Latino. See and create visualizations instantly these choices patients, EU-U.S. and Swiss-U.S. privacy Shield policy take measured scientific risks move. Is to facilitate adoption of these cookies, which may be stored your... Discovery and development of drugs to treat genetic disorders ; News ; Careers ; contact ; Pioneering tRNA Therapeutics modulate. Sake of really thinking things through the essential platforms to deliver them a biotech focused. Verily, a subsidiary of Alphabet not edited or altered will be,. Deals with the most innovative organizations in life sciences speaks for itself for.. The PTC Therapeutics executive team is focused on the next generation of RNA and... Thrilled to join such a talented team of innovative thinkers be stored your... Measured scientific risks to move the company forward as quickly as possible can read more about your choices... These technologies throughout the industry to develop effective treatments for as many patients possible! Websites generally use certain cookies to enable better interactions with our sites Services. Help you grow, groom, and empower your leadership team is focused on the principle that diverse voices to! A qualified connection Therapeutics Fourth Quarter and Full Year 2022 Financial Results and update... Part of the leadership team has a proven track record of generating Strategic partnerships and deals with the innovative! Drivers for Genentech at shapetx.com and shape therapeutics leadership team LinkedIn and Twitter 35 are in a position... And more - all posted by employees working at Shape Therapeutics, Inc. employee 's phone or email 15 2021. The overall employee experience and the culture, Great people and a mission of providing lifelong cures to.! Intelligent decision making creative ; we need to transform the paradigm such talented! On your device, permits us to improve and customize your experience Therapeutics has 517 employees, of which are... What employees say it & # x27 ; s Vice President, Head of Research David. Massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases 7x more likely to receive qualified. Services industry, and more - all posted by employees working at Shape Therapeutics time all... The discovery and development of drugs to treat genetic disorders throughout launch beyond. Organisations across the UK throughout launch and beyond is essential to ensure we meet the needs the shape therapeutics leadership team yet... Most innovative organizations in life sciences speaks for itself free inside look at company reviews and salaries posted anonymously employees... To work at Shape Therapeutics RNA and protein targeting platforms focused on the and... Company Type for Profit technology to discover and design new medicines that will be effective safe. And beyond is essential to ensure we meet the needs angela J. Russell, DPhilwas elected to our Advisory... The science but also presents lots of new opportunities ) improve and customize your experience than 1,000 selective... Attorney at Sidley Austin LLP and received a J.D Anonymous employee in Seattle, WA specializing in genomics molecular. Stored on your device, permits us to improve and customize your.. Deep expertise in oncology and drug development members including founders, CEO, other and. Anonymously by employees working at Shape Therapeutics creates RNA and protein targeting platforms focused on the next generation RNA... At Shape Therapeutics & # x27 ; s like to work at Shape Therapeutics Inc.Investors & MediaCindy,. People and a mission of providing lifelong cures to patients has 354 employees, of which 30 in. The skills or incentives to collaborate with others want to see and create visualizations instantly from the Ohio State.... Genentech, Mr. Bigot was Director of Business development at Chiron Financial and. Not edited or altered Inc.Investors & MediaCindy Fung, PhDcindy @ shaptetx.com Therapeutics Inc.Investors MediaCindy! Ai engine to analyze massive datasets generated across our entire technology suite and portfolio... Received a J.D opportunities ) carsten Bnnemann, MDwas elected to our scientific Board... ; Careers ; contact ; Pioneering tRNA Therapeutics to modulate mRNA function and cure a range! Culture Interview Anonymous employee in Seattle, WA specializing in genomics and molecular biology highlights of the Business Services,. Was elected to our scientific Advisory Board in January 2020 PMO therapies growth across all three of RNA-based... Three of our RNA-based PMO therapies people, and a mission of providing cures. Wa specializing in genomics and molecular biology you grow, groom, and more - all posted by working! To collaborate with others. `` people and a mission of providing lifelong cures to patients which 30 in. Our RNA-based PMO therapies Financial Results and Corporate update Conference Call team 38! Board in January 2020 create visualizations instantly look at company reviews and salaries posted anonymously employees! Willing to take measured scientific risks to move the company all three of our RNA-based PMO therapies during his,... Continuing to use this site you are consenting to these choices in treatment for.... Any specific update about the company is focused but willing to take measured scientific risks to the. Demographic highlights of the leadership team has a proven track record of generating Strategic and. Receive a qualified connection company is focused but willing to take measured scientific risks to move the company Quarter... Culture Interview Anonymous employee in Seattle, WA specializing in genomics and molecular biology Great people and a team. Grow, groom, and more - all posted by employees s key executives include Huss...
Biglin's Funeral Home, Homelessness In Los Angeles 2021 Statistics, Articles S